Children with pulmonary arterial hypertension and prostanoid therapy: Long-term hemodynamics

Journal of Heart and Lung Transplantation

Volumn 32, Issue 5, 2013, Pages 546-552

  Siehr, Stephanie L ^a   Dunbar Ivy, D ^b   Miller Reed, Kathleen ^b   Ogawa, Michelle ^a   Rosenthal, David N ^a   Feinstein, Jeffrey A ^a  

^a STANFORD UNIVERSITY   (United States)

^b Children's Hospital Colorado   (United States)

Author keywords

epoprostenol; hemodynamics; pediatric patients; pulmonary arterial hypertension; treprostinil

Indexed keywords

PROSTACYCLIN; TREPROSTINIL;

ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CHILD; CHILDHOOD MORTALITY; DESCRIPTIVE RESEARCH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART LUNG TRANSPLANTATION; HEART RIGHT ATRIUM PRESSURE; HUMAN; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY SYSTEMIC VASCULAR RESISTANCE; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; SYSTEMIC VASCULAR RESISTANCE;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, SUBCUTANEOUS; LONGITUDINAL STUDIES; MALE; PROSTAGLANDINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84876046035     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2013.01.1055     Document Type: Article

References (26)

1. G.E. D'Alonzo, R.J. Barst, and S.M. Ayres Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 1991 343 349
2. A. Rashid, and D. Ivy Severe paediatric pulmonary hypertension: new management strategies Arch Dis Child 90 2005 92 98
3. E.B. Rosenzweig, A.C. Widlitz, and R.J. Barst Pulmonary arterial hypertension in children Pediatr Pulmonol 38 2004 2 22
4. P.M. Mourani, M.K. Sontag, D.D. Ivy, and S.H. Abman Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease J Pediatr 154 2009 379-84, 384 e371-2
5. T. Humpl, J.T. Reyes, H. Holtby, D. Stephens, and I. Adatia Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study Circulation 111 2005 3274 3280
6. R. Barst Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension Clin Pharmacol Therapeut 73 2003 372 382
7. E.B. Rosenzweig, D.D. Ivy, and A. Widlitz Effects of long-term bosentan in children with pulmonary arterial hypertension J Am Coll Cardiol 46 2005 697 704
8. D.D. Ivy, A.K. Doran, and K.J. Smith Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension J Am Coll Cardiol 51 2008 161 169
9. S.G. Haworth, and A.A. Hislop Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006 Heart 95 2009 312 317
10. R.L. van Loon, M.T. Roofthooft, and T. Delhaas Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies Am J Cardiol 106 2010 117 124
11. L.J. Rubin, B.M. Groves, J.T. Reeves, M. Frosolono, F. Handel, and A.E. Cato Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension Circulation 66 1982 334 338
12. V.V. McLaughlin, D.E. Genthner, M.M. Panella, and S. Rich Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension N Engl J Med 338 1998 273 277
13. R.J. Barst, L.J. Rubin, and W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 301
14. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
15. O. Sitbon, M. Humbert, and H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
16. A.E. Lammers, A.A. Hislop, Y. Flynn, and S.G. Haworth Epoprostenol treatment in children with severe pulmonary hypertension Heart 93 2007 739 743
17. D. Yung, A.C. Widlitz, E.B. Rosenzweig, D. Kerstein, G. Maislin, and R.J. Barst Outcomes in children with idiopathic pulmonary arterial hypertension Circulation 110 2004 660 665
18. E.B. Rosenzweig, D. Kerstein, and R.J. Barst Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects Circulation 99 1999 1858 1865
19. R.J. Barst, G. Maislin, and A.P. Fishman Vasodilator therapy for primary pulmonary hypertension in children Circulation 99 1999 1197 1208
20. R.J. Barst, N. Galie, and R. Naeije Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Eur Respir J 28 2006 1195 1203
21. V.V. McLaughlin, S.P. Gaine, and R.J. Barst Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension J Cardiovasc Pharmacol 41 2003 293 299
22. M. Gomberg-Maitland, V.F. Tapson, and R.L. Benza Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension Am J Respir Crit Care Med 172 2005 1586 1589
23. M. Levy, D.S. Celermajer, E. Bourges-Petit, M.J. Del Cerro, F. Bajolle, and D. Bonnet Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension J Pediatr 158 2011 584 588
24. D.T. Balzer, H.W. Kort, and R.W. Day Inhaled nitric oxide as a preoperative test (INOP test I: The INOP Test Study Group Circulation 106 2002 I76 I81
25. A. Bergstra, R.B. van Dijk, H.L. Hillege, K.I. Lie, and G.A. Mook Assumed oxygen consumption based on calculation from dye dilution cardiac output: an improved formula Eur Heart J 16 1995 698 703
26. L. Melnick, R.J. Barst, C.A. Rowan, D. Kerstein, and E.B. Rosenzweig Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension Am J Cardiol 105 2010 1485 1489